Pharmaceutical company · GRFS

Grifols
clinical trial
pipeline

Registry checked

Published

Alpha1-Proteinase Inhibitor is linked to 1 distinct active study, with 1 Phase 3. Alpha1-Proteinase Inhibitor 15% is linked to 1 distinct active study, with 1 Phase 3.

Phase 3 study NCT07555483 in Alpha 1 Antitrypsin Deficiency lists estimated primary completion on 30 September 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

6active trials
as lead sponsor
  • Phase 10
  • Phase 20
  • Phase 36
  • Phase 40
  • Phase not recorded0

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

72 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

02Primary completion

Primary completion moved earlier

2028-12 (estimated)2011-12 (actual)
Dec 2028Dec 2011

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

NCT00319228 · ClinicalTrials.gov
Recorded by ComplyRx
07 Oct 2026
Registry last updated
07 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-071110251
2026-10-080000000
2026-10-090000000
2026-10-100000221
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals1110472 distinct

02 / Drugs & programmes

Explore the pipeline

5 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Alpha1-Proteinase Inhibitor

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Next primary completion
Not reported
Open drug

Alpha1-Proteinase Inhibitor 15%

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Alpha 1 Antitrypsin Deficiency
Next primary completion
30 September 2027 · estimated
Open drug

Gamunex-C

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Next primary completion
Not reported
Open drug

Trimodulin

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Community-acquired Pneumonia
Next primary completion
Not reported
Open drug

Xembify

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
B-cell Chronic Lymphocytic Leukemia · Bacterial Infections · Hypogammaglobulinemia
Next primary completion
Not reported
Open drug

5 of 6 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

5 selected programmes · accepted investigational links cover 5 of 6 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Grifols trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
SWIFT-SC
Alpha1-Proteinase Inhibitor 15%

NCT07555483

Phase 3 · Recruiting

Trial source and qualifications

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 05 May 2026 · actual
    Primary completion: 30 Sept 2027 · estimated
    Study completion: 30 Sept 2027 · estimated

    2021202220232024202520262027202820292030
    XPERT
    Gamunex-C

    NCT07540221

    Phase 3 · Recruiting

    Trial source and qualifications

    A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    No eligible observations recorded in the inspected period.

      Start: 02 Apr 2026 · actual
      Primary completion: 31 Dec 2027 · estimated
      Study completion: 31 Dec 2027 · estimated

      2021202220232024202520262027202820292030
      ESsCAPE
      Trimodulin

      NCT05722938

      Phase 3 · Recruiting

      Trial source and qualifications

      Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 09 Sept 2023 · actual
        Primary completion: 31 Jul 2028 · estimated
        Study completion: 31 Jul 2028 · estimated

        2021202220232024202520262027202820292030
        SIGMA
        Asset mapping not recorded

        NCT07582432

        Phase 3 · Recruiting

        Trial source and qualifications

        A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 11 May 2026 · actual
          Primary completion: 31 Aug 2028 · estimated
          Study completion: 31 Aug 2028 · estimated

          2021202220232024202520262027202820292030
          SPARTA-OLE
          Alpha1-Proteinase Inhibitor

          NCT02796937

          Phase 3 · Enrolling by invitation

          Trial source and qualifications

          Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

          Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

          Start clipped at the display horizon.

          0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          No eligible observations recorded in the inspected period.

            Start: Jul 2016 · actual
            Primary completion: Sept 2028 · estimated
            Study completion: Feb 2029 · estimated

            2021202220232024202520262027202820292030
            EXCELL
            Xembify

            NCT05645107

            Phase 3 · Recruiting

            Trial source and qualifications

            A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

            Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

            1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

            ClinicalTrials.gov source

            1 inspected observations omitted. At most three verified observations are shown, not full history.

              Start: 26 Dec 2022 · actual
              Primary completion: Aug 2029 · estimated
              Study completion: Aug 2029 · estimated

              2021202220232024202520262027202820292030

              Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

              6 selected of 6 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 0 past estimates, 0 outside the horizon, 0 contradictory dates.

              04 / Therapeutic focus

              Where the activity is

              2

              active trials in Oncology

              Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

              Active trials by primary therapeutic area

              • Oncology2 trials
              • Respiratory2 trials
              • Genetic & Rare Disease1 trials
              • Neurology1 trials
              • Unmapped0 trials
              • Healthy volunteers0 trials

              Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

              06 / Related companies

              All companies
              C

              CSL

              Shared indexed programme context · 1 selected asset

              T

              Takeda

              Shared indexed programme context · 1 selected asset

              Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

              Sources, scope and methodology

              ClinicalTrials.gov lead-sponsor scope

              Enumerated controlled company group covers 102 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Grifols, S.A. · Grifols Therapeutics LLC · Grifols Biologicals, LLC. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

              ClinicalTrials.gov

              Attribution coverage

              112 distinct registry candidates produced 102 accepted studies. 0 mapped to other owners, 10 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 6 unverified, 6 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

              Indexed enrichment

              102 scoped records have indexed enrichment and 0 do not. Missing enrichment does not remove a trial from cohort counts.

              Scope observation

              The successful attribution check completed at 2026-11-01T04:03:01.488Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 5b13d546475ea52f96f9569b17c33782fa3e471b3daaca0022b6fd313c653670.

              Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

              Dated canonical-attribution snapshot: 102 mapped lead-sponsored clinical studies across all statuses. 102 have indexed enrichment. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

              Keep following
              what matters.

              Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

              Build your watch

              Choose what to track in the watch builder.